Suchergebnisse - "Reich, Kristian"

PubPharm (527)

1

Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years

enthalten in: Allergy | 2024

von Guttman-Yassky, E. | Kabashima, K. | Staumont-Salle, D. | +10

2

Summary of Research : An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study

enthalten in: Advances in therapy | 2024

von Guttman-Yassky, E. | Simpson, E. | Reich, K. | +7

3

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab : A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

enthalten in: Dermatology and therapy | 2024

von Reich, K. | Bianchi, L. | Khemis, A. | +6

4

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

enthalten in: Dermatology and therapy | 2024

von Reich, K. | Bianchi, L. | Khemis, A. | +6

5

Hidradenitis suppurativa : new insights into disease mechanisms and an evolving treatment landscape

enthalten in: The British journal of dermatology | 2024

von Krueger, J. | Frew, J. | Jemec, G. | +8

CommentIn: Br J Dermatol. 2024 Jan 23;190(2):e14. - PMID 38262602

6

Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study

enthalten in: Advances in therapy | 2024

von Guttman-Yassky, E. | Simpson, E. | Reich, K. | +7

7

Correction to : Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids

enthalten in: American journal of clinical dermatology | 2024

von Silverberg, J. | Armstrong, A. | Blauvelt, A. | +1

ErratumFor: Am J Clin Dermatol. 2023 Nov;24(6):913-925. - PMID 37695504

8

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials : a case study in psoriasis

enthalten in: The Journal of dermatological treatment | 2023

von Signorovitch, J. | Diels, J. | Van Sanden, S. | +6

9

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2

enthalten in: Dermatology and therapy | 2023

von Kim, B. | Jo, S. | Youn, S. | +6

10

Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply

enthalten in: Lancet (London, England) | 2023

von Guttman-Yassky, E. | Simpson, E. | Reich, K. | +7

CommentOn: Lancet. 2023 Nov 18;402(10415):1833-1834. - PMID 37980089

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[53]